3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria.
Am J Cardiol. 2011 Oct 15;108(8):1188-95. doi: 10.1016/j.amjcard.2011.06.024. Epub 2011 Jul 26.
The aim of this study was to investigate whether preoperative determination of plasma copeptin levels in addition to plasma N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) could help improve risk stratification in patients who undergo major vascular surgery. One hundred ninety-eight consecutive patients who underwent major vascular surgery (58.6% infrainguinal aortic reconstruction, 23.7% abdominal aortic aneurysm surgery, 17.7% carotid endarterectomy) were included in this study. Patients were monitored for in-hospital and long-term (2-years) major adverse cardiac events, consisting of cardiac death, nonfatal myocardial infarction, and emergent coronary revascularization. Overall, 40 patients (20.2%) reached the primary end point, and most of these events occurred during the index hospital stay (n = 18 [45%]). In univariate Cox regression analysis, increasing concentrations of copeptin were significant determinants of outcome as a continuous variable (hazard ratio [HR] 1.012, p = 0.005) and as a dichotomized variable according to the recommended cutoff of 14.0 pmol/L (HR 4.116, p <0.001). Subgroup analyses revealed that especially patients at low estimated risk according to plasma NT-pro-BNP levels were at significantly higher risk for worse outcomes with higher copeptin levels (HR 5.983, p = 0.002). In multivariate Cox regression analysis, copeptin concentrations >14 pmol/L were significant independent predictors of outcome (HR 2.842, p = 0.002) in addition to type of surgery, history of myocardial infarction, elevated levels of cardiac troponin T, and NT-pro-BNP levels. In conclusion, the results of this study suggest that preoperative determination of this new biomarker could substantially improve prediction of perioperative and postoperative outcomes in vascular surgery patients.
本研究旨在探讨术前测定血浆 copeptin 水平是否有助于改善行大血管手术患者的风险分层。本研究纳入 198 例连续行大血管手术的患者(58.6%下肢动脉重建术,23.7%腹主动脉瘤手术,17.7%颈动脉内膜切除术)。患者接受住院期间和长期(2 年)主要不良心脏事件(包括心脏性死亡、非致死性心肌梗死和紧急冠状动脉血运重建)监测。共有 40 例患者(20.2%)达到主要终点,其中大多数事件发生在指数住院期间(n=18[45%])。在单因素 Cox 回归分析中,c肽浓度的升高是作为连续变量(风险比[HR]1.012,p=0.005)和根据推荐的 14.0 pmol/L 截断值作为二分类变量的结果的重要决定因素。亚组分析显示,特别是根据血浆 NT-pro-BNP 水平评估风险较低的患者,随着 copeptin 水平的升高,其预后不良的风险显著增加(HR 5.983,p=0.002)。在多因素 Cox 回归分析中,c肽浓度>14 pmol/L 是手术类型、心肌梗死史、心肌肌钙蛋白 T 水平升高和 NT-pro-BNP 水平以外的独立预后预测因素(HR 2.842,p=0.002)。总之,本研究结果表明,术前测定这种新型生物标志物可显著改善血管外科患者围手术期和术后结局的预测。